Λίστα αντικειμένων
Our previous evaluation, publisehd in BMT revealed the higher GvHD and TRM in mismatched PBSCT. We discussed our prospective study adding either MMF or 1 day post-Cy in our current 20mg Camoth anti GvHD practice.We also discussed the paper "Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide" punblished in Blood advances (cave refers to BMT patients)
We ended th we change our policy in our HLA mismatched PBSCT and we will evaluate whether the addtion of MMF or post Cy wiull be better. Responsible for the rpotocol wil be Dr. Liga.
Lecturer: Spyridonidis
Participants: all medical staff